Furthermore, dual blockade of either CD39 or A2AR together with TIGIT significantly increased AML cell lysis in 2/3 cell lines in comparison to both a single blockade respectively and the control treatment. The gene discussed is ENTPD1; the disease is acute myeloid leukemia.